The short version
What teams need to understand
- All identified regulatory changes must be assessed for impact on the pharmacovigilance system.
- Impact assessment must include gap analysis against current processes and regulatory requirements.
- Changes must be classified based on risk and compliance impact.
- Assessment outcomes must drive clear and documented action plans.
- Decision-making must be structured, justified, and approved by appropriate roles.
- Inspection-ready evidence must demonstrate that regulatory changes are systematically assessed and acted upon.
Regulatory expectation
What regulators expect
Each expectation should be supported by controlled documentation, traceable records, clear ownership, and evidence that the process works in practice.
- Regulatory changes must be assessed for impact.
- Gap analysis must identify required changes.
- Risk classification must guide prioritisation.
- Actions must be defined and assigned.
- Decisions must be documented and approved.
Why it matters
What this means in practice
Inspectors assess whether pharmacovigilance systems perform structured impact assessments of regulatory changes. They review gap analysis, risk classification, decision-making processes, and evidence that appropriate actions are defined and implemented.
Questions this page answers
Inspection evidence
Evidence teams should be able to show
Regulatory Impact Assessment Forms
- Structured assessment documentation for each regulatory change
- Description of regulatory change and source
- Assigned responsible assessor
- Documented evaluation of impact
Gap Analysis Documentation
- Comparison between current processes and new requirements
- Identification of non-compliant areas
- Analysis of impacted SOPs, systems, and functions
- Documentation of required changes
Risk and Impact Classification
- Categorisation of changes as critical, high, medium, or low impact
- Assessment of regulatory and operational risk
- Justification of assigned risk level
- Prioritisation of actions based on risk
Action Planning and Assignment
- Defined actions required to achieve compliance
- Assignment of responsible owners
- Defined timelines for implementation
- Tracking of action completion
Decision-Making and Approval Records
- Documented decisions on applicability and required actions
- Approval by PV, QA, or regulatory leadership
- Justification for decisions made
- Evidence of management involvement for high-impact changes
Regulatory Basis (Primary Sources)
- GVP Module I - requirement for PV system compliance and quality management
- GVP Module VI - requirement to align safety processes with regulatory requirements
- ICH E2E - requirement to anticipate and manage regulatory changes
- MHRA GPvP guidance - expectations for evaluating regulatory requirements
- FDA pharmacovigilance guidance - requirement to implement regulatory changes effectively
Typical Inspection Questions (What Inspectors Ask)
- How do you assess the impact of regulatory changes?
- Show me your impact assessment for this update.
- What gaps did you identify?
- How did you decide what actions to take?
- Who approved the decision?
Common failure patterns
What good looks like
- Structured and documented impact assessment process.
- Clear gap analysis linking regulatory requirements to internal processes.
- Defined risk classification and prioritisation.
- Well-defined action plans with ownership and timelines.
- Documented and approved decision-making.
How teams operationalise it
- Use structured templates to assess regulatory changes.
- Perform gap analysis against current PV processes.
- Classify impact based on risk and regulatory importance.
- Define actions required to achieve compliance.
- Assign responsibility and timelines for implementation.
- Document and approve decisions within governance processes.
From expectation to working control
Find the documentation that supports this work
Review the related toolkit to understand its purpose, included files, and how it supports this regulatory expectation.
Frequently asked questions
What is a regulatory intelligence impact assessment?
It is a structured evaluation of how a regulatory change affects a company's pharmacovigilance system and what actions are required to remain compliant.
What is gap analysis in pharmacovigilance?
Gap analysis compares current processes against new regulatory requirements to identify areas that require updates or changes.
How do companies decide what actions to take after regulatory updates?
Actions are defined based on impact assessment, risk classification, and gap analysis, and are approved through structured decision-making processes.
Do inspectors review regulatory impact assessments?
Yes. Inspectors review whether regulatory changes are assessed properly and whether decisions and actions are documented.
Why is risk classification important in regulatory intelligence?
Risk classification helps prioritise actions and ensures that critical regulatory changes are addressed promptly.
What happens if regulatory changes are not assessed properly?
Failure to assess regulatory changes can lead to non-compliance, inspection findings, and potential regulatory action.
Source boundary
Regulatory sources
These primary sources inform this structured interpretation. Always confirm current requirements against the original source and the requirements applicable to your organisation, product, and jurisdiction.
European Medicines Agency (EMA)
Guideline on good pharmacovigilance practices (GVP) - Module I
View sourceGuideline on good pharmacovigilance practices (GVP) - Module VI
View source
FDA
FDA Postmarketing Safety Reporting
View source
ICH
ICH E2E Pharmacovigilance Planning
View source
MHRA
Good Pharmacovigilance Practice (GPvP)
View source